Patients with the deadliest cancer finally have something that works

Pancreatic cancer, often diagnosed late and resistant to treatments, has finally seen a breakthrough. On August 26, the U.S. Food and Drug Administration approved Rasonque, a once-daily pill from Revolution Medicines. This marks the first broad RAS-targeted medicine cleared for adults with metastatic pancreatic cancer who have undergone chemotherapy.

RAS mutations cause over 90% of pancreatic tumors, making it a crucial target in cancer research. However, drugmakers struggled for years to effectively target this protein. Rasonque directly attacks several forms of mutated RAS, nearly doubling median overall survival in a key trial.

The FDA approved Rasonque about five weeks after accepting the application, thanks to its fast-tracked status. Despite this promising data, Revolution Medicines' stock remained relatively flat on the approval day, as the market had already anticipated the news. The drug's $39,800 price tag for a 30-day supply was also covered by some insurance plans, reducing out-of-pocket costs for commercially insured patients.

However, the approval brings several challenges. Insurance coverage, especially for Medicare and commercial payers, will significantly impact commercial success due to Rasonque's high price. Rival drugs targeting RAS are also in development, posing long-term competition risks. Revolution Medicines is also exploring Rasonque's use in lung cancer and other RAS-driven tumors, which could broaden its market.

This approval signals a significant milestone after years of failed attempts to target RAS in cancer. It opens the door for more RAS-based medicines in various tumor types, driven by the breakthrough achieved by Revolution Medicines.